Latecomer Brigatinib Looking Good In First-Line NSCLC Head-To-head
Takeda's ALK inhibitor meets primary endpoint in interim analysis from critical first-line lung cancer head-to-head study, helping validate Ariad acquisition, but will be a relative class latecomer to the setting.
You may also be interested in...
Takeda's Phase III win over Pfizer's Xalkori leaves oncologists cheering, but hankering for a head-to-head study against Alecensa, which is becoming the standard of care in the US for first-line ALK+ NSCLC.
In this week's podcast edition of Five Must-Know Things: alarms sound over Omicron; Sanofi boosts vaccine pipeline via acquisition; J&J’s immunology plans; Chinese firms step onto world stage; and top execs share insights to shape India’s R&D push.
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.